Thiazolidinediones × glycemic control

TrialDiabetes & metabolism journal2026

Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial.

Jun Hwa Hong et al.PubMed ↗Full text ↗Publisher ↗

  • Pioglitazone 30 mg/day add-onlooks good hereLower long-term blood sugar, no range given.No ranges given.

What the trial testedas reported · 246 people · 2026

No range given

Reported lower long-term blood sugar, no range given

−0.80percentage points

pioglitazone 30 mg/day add-on vs placebo

As reported

difference −0.80 %, no interval · the paper's word: HbA1c

Who was studied, and how

246people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

pioglitazone 30 mg/day add-on
placebo

Reported lower long-term blood sugar, no range given−0.80

randomised

the abstract, start to end

24 weeks treatment reduced from 7.8%±0.8% to 7.0%±0.6% (P<0.0001).

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
HbA1cpioglitazone 30 mg/day add-on vs placebo
−0.80
ThiazolidinedionesGlycemic control

Thiazolidinediones × glycemic controlhelps?settled

unlikelylikely
0.830.80 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 6

2 papers cite it

2026
this papercites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 41151541